VYALEV™ is a combination injectable medication consisting of foscarbidopa (an aromatic amino acid decarboxylation inhibitor) and foslevodopa (an aromatic amino acid), which is designed to provide continuous dopaminergic stimulation through subcutaneous administration. The drug is administered via a specialized infusion pump (VYAFUSER), typically in the abdominal region, allowing for precise control over the delivery of the medication. It is used to address motor fluctuations in patients with advanced Parkinson's disease who require more consistent dopaminergic therapy to manage the progressive symptoms of their condition.

VYALEV is a highly effective treatment for managing "off" episodes and motor control in Parkinson’s disease patients. It combines the benefits of foscarbidopa and foslevodopa, ensuring that levodopa is optimally available to the brain while minimizing peripheral conversion and side effects. As a subcutaneous infusion, it offers patients an alternative to oral medication regimens, ensuring more stable blood levels of levodopa, which can lead to a reduction in motor fluctuations. This method of delivery is particularly useful for those with advanced disease and significant daily motor disability.